SGH
Sivik Global Healthcare Portfolio holdings
AUM
$224M
This Quarter Return
+19.54%
1 Year Return
+5.3%
3 Year Return
+45.33%
5 Year Return
+103.79%
10 Year Return
+430.94%
AUM
$269M
AUM Growth
+$269M
(+36%)
Cap. Flow
+$44.8M
Cap. Flow
% of AUM
16.7%
Top 10 Holdings %
Top 10 Hldgs %
31.54%
Holding
57
New
12
Increased
18
Reduced
17
Closed
7
Top Buys
| 1 |
Bristol-Myers Squibb
BMY
|
$8.35M |
| 2 |
Amgen
AMGN
|
$6.03M |
| 3 |
Centene
CNC
|
$5.97M |
| 4 |
Biogen
BIIB
|
$5.94M |
| 5 |
Zimmer Biomet
ZBH
|
$5.24M |
Top Sells
| 1 |
WCG
Wellcare Health Plans, Inc.
WCG
|
$5.18M |
| 2 |
Becton Dickinson
BDX
|
$5.06M |
| 3 |
CELG
Celgene Corp
CELG
|
$4.97M |
| 4 |
Alcon
ALC
|
$3.11M |
| 5 |
Quest Diagnostics
DGX
|
$2.4M |
Sector Composition
| 1 | Healthcare | 99.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Humana
HUM
$36.5B
| $10.1M | 3.74% |
27,500
-1,500
| -5% | -$550K |
|
2
HCA Healthcare
HCA
$94.5B
| $9.24M | 3.43% |
62,500
+2,500
| +4% | +$370K |
|
|
3
Centene
CNC
$14.3B
| $8.49M | 3.15% |
135,000
+95,000
| +238% | +$5.97M |
|
|
4
Bristol-Myers Squibb
BMY
$96B
| $8.35M | 3.1% |
+130,000
| New | +$8.35M |
|
5
Elevance Health
ELV
$71.8B
| $8.31M | 3.08% |
27,500
+12,500
| +83% | +$3.78M |
|
6
Cigna
CI
$80.3B
| $8.18M | 3.04% |
40,000
+20,000
| +100% | +$4.09M |
|
7
Tenet Healthcare
THC
$16.3B
| $8.18M | 3.03% |
215,000
+40,000
| +23% | +$1.52M |
|
8
UnitedHealth
UNH
$281B
| $8.08M | 3% |
27,500
+2,500
| +10% | +$735K |
|
9
Boston Scientific
BSX
$156B
| $7.91M | 2.94% |
175,000
-25,000
| -13% | -$1.13M |
|
10
Universal Health Services
UHS
$11.6B
| $7.89M | 2.93% |
55,000
+5,000
| +10% | +$717K |
|
11
Danaher
DHR
$147B
| $7.67M | 2.85% |
50,000
+5,000
| +11% | +$767K |
|
12
Sanofi
SNY
$121B
| $7.53M | 2.8% |
150,000
+10,000
| +7% | +$502K |
|
13
Regeneron Pharmaceuticals
REGN
$61.5B
| $7.51M | 2.79% |
20,000
| – | – |
|
14
Intuitive Surgical
ISRG
$170B
| $7.39M | 2.74% |
12,500
+6,382
| +104% | +$3.77M |
|
15
Vertex Pharmaceuticals
VRTX
$100B
| $7.12M | 2.64% |
32,500
-7,500
| -19% | -$1.64M |
|
16
Merck
MRK
$210B
| $6.82M | 2.53% |
75,000
-10,000
| -12% | -$909K |
|
17
BioMarin Pharmaceuticals
BMRN
$11.2B
| $6.76M | 2.51% |
80,000
+35,000
| +78% | +$2.96M |
|
18
Eli Lilly
LLY
$657B
| $6.57M | 2.44% |
50,000
-5,000
| -9% | -$657K |
|
19
Grifois
GRFS
$6.78B
| $6.41M | 2.38% |
275,000
-20,000
| -7% | -$466K |
|
20
AstraZeneca
AZN
$248B
| $6.23M | 2.31% |
125,000
+45,000
| +56% | +$2.24M |
|
|
21
Amgen
AMGN
$155B
| $6.03M | 2.24% |
+25,000
| New | +$6.03M |
|
|
22
Biogen
BIIB
$19.4B
| $5.94M | 2.2% |
+20,000
| New | +$5.94M |
|
23
Baxter International
BAX
$12.7B
| $5.85M | 2.17% |
70,000
-5,000
| -7% | -$418K |
|
24
Thermo Fisher Scientific
TMO
$186B
| $5.69M | 2.11% |
17,500
+2,500
| +17% | +$812K |
|
25
Bio-Rad Laboratories Class A
BIO
$8.06B
| $5.55M | 2.06% |
15,000
-3,000
| -17% | -$1.11M |
|